Psoriatic arthritis study using ultrasound to track activity
Part of Bones, joints & muscles, Skin clinical trials.
This study uses power Doppler ultrasound to classify and measure how active your psoriatic arthritis is. It may help doctors better understand and treat your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have psoriatic arthritis as diagnosed by a doctor using standard criteria.
- You are willing to follow the study schedule, treatments, and tests.
- You can give your permission to be in the study.
- You have not had another type of arthritis in the past year.
- You do not have an active infection or a chronic infectious disease.
- You are not pregnant or breastfeeding, and you can tolerate having blood drawn.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether IL-17 inhibitor medications can reduce inflammation in tendons and ligaments that is not visible on the skin but can be detected with a special ultrasound. It may be an option for people with moderate to severe psoriasis who have not had enough relief from creams or light therapy.
This study uses ultrasound and a special technique called elastography to look at the health of tendons in people with psoriatic arthritis compared to healthy volunteers. The information may help doctors better understand and manage the disease.
This trial studies people with psoriatic arthritis who have painful Achilles tendon insertion with signs of inflammation on ultrasound. It may help researchers better understand what drives tendon inflammation and how it can be treated.
This study looks at how well upadacitinib treats enthesitis (pain where tendons or ligaments attach to bone) in people with psoriatic arthritis. Researchers will use ultrasound to measure improvement. The trial is for adults who have already tried at least one biologic drug, including an anti-TNF, without success.
This trial compares two drugs, apremilast and adalimumab, to see which is more effective for people with psoriatic arthritis who have not responded well to methotrexate. It focuses on joint pain, swelling, and skin symptoms.
This study looks at how inflammatory “cytokines” are expressed in people with psoriasis—both those with joint involvement and those without. It may help researchers understand what drives joint disease and guide better future monitoring or treatments.
Hear when a new Psoriatic Arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.